EGFR共突变对非小细胞肺癌患者治疗和预后影响的研究进展  

Impact of EGFR co-mutation on the treatment and prognosis of patient with non-small cell lung cancer

作　　者：刘灵丽 廖德华[3] 杨农 LIU Ling-li;LIAO De-hua;YANG Nong(University of South China,Hengyang Hunan 421001;Department of Lung and Gastrointestinal Cancer,Hunan Cancer Hospital,Changsha 410013;Department of Pharmacy,Hunan Cancer Hospital,Changsha 410013)

机构地区：[1]南华大学,湖南衡阳421001 [2]湖南省肿瘤医院/中南大学湘雅医学院附属肿瘤医院肺胃肠内科,长沙410013 [3]湖南省肿瘤医院药学部,长沙410013

出　　处：《中南药学》2021年第10期2111-2117,共7页Central South Pharmacy

基　　金：湖南省自然科学基金(No.2020JJ3025);吴阶平基金会临床药学科研专项(No.320.6750.2020-04-34);湖南省医学会医学科研基金(No.HMA202001005)。

摘　　要：表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)的临床应用给存在EGFR突变的肺癌患者带来了曙光,但是随着二代测序技术的发展与完善,越来越多的EGFR共突变事件被发现,且提示其与预后较差相关。近年来,聚焦于EGFR共突变的临床研究受到极大的关注,但是针对其的治疗手段存在争议,目前对于此类患者的治疗策略选择尚无定论。本文对近几年国内外关于EGFR共突变对非小细胞肺癌治疗及预后的影响进行综述,以期为此类患者的治疗提供思路。The clinical application of epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKIs)have exhibited dramatic prospects for patients with non-small cell lung cancer(NSCLC).However,with the development and maturation of sequencing technology,multiple EGFR co-mutation were found and suggested poor prognosis.In recent years,though clinical studies on EGFR co-mutation have attracted much attention,there are limited treatment options available for these patients.This review summarized the impact of EGFR co-mutation on the treatment and prognosis of NSCLC,which may provide new ideas for the targeted therapy for patients with NSCLC.

关 键 词：非小细胞肺癌 EGFR共突变 

分 类 号：R734.2[医药卫生—肿瘤]